Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
OwnerDevalina Law, Rodger Henry +1inventors
InventorsDevalina Law, Rodger Henry, Xiaochun Lou
Life of this patent
Estimating the term…
Abstract
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
Claims9
A crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
Crystalline cefdinir anhydrate having substantial crystalline purity, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
Crystalline cefdinir anhydrate having substantial crystalline purity and substantial chemical purity, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
Crystalline cefdinir anhydrate having substantial crystalline purity, substantial chemical purity, and substantial isomeric purity, said novel crystalline cefdinir anhydrate characterized, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
A composition comprising a crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
A mixture comprising Cefdinir Crystalline Form A and a crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
A composition comprising Cefdinir Crystalline Form A and a crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and a crystalline cefdinir anhydrate, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.5°, 10.9°, 12.6°, 14.7°, 16.6°, 21.8° and 27.3°.
Dependencies are inferred from the claim text.